132 related articles for article (PubMed ID: 23060423)
1. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans.
Pavri BB; Greenberg HE; Kraft WK; Lazarus N; Lynch JJ; Salata JJ; Bilodeau MT; Regan CP; Stump G; Fan L; Mehta A; Wagner JA; Gutstein DE; Bloomfield D
Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1193-201. PubMed ID: 23060423
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
[TBL] [Abstract][Full Text] [Related]
4. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Regan CP; Kiss L; Stump GL; McIntyre CJ; Beshore DC; Liverton NJ; Dinsmore CJ; Lynch JJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):322-30. PubMed ID: 17967939
[TBL] [Abstract][Full Text] [Related]
5. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
6. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation.
Tanaka H; Hashimoto N
Cardiovasc Drug Rev; 2007; 25(4):342-56. PubMed ID: 18078434
[TBL] [Abstract][Full Text] [Related]
7. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
Regan CP; Wallace AA; Cresswell HK; Atkins CL; Lynch JJ
J Pharmacol Exp Ther; 2006 Feb; 316(2):727-32. PubMed ID: 16243963
[TBL] [Abstract][Full Text] [Related]
8. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat.
de Haan S; Greiser M; Harks E; Blaauw Y; van Hunnik A; Verheule S; Allessie M; Schotten U
Circulation; 2006 Sep; 114(12):1234-42. PubMed ID: 16940189
[TBL] [Abstract][Full Text] [Related]
9. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.
Ravens U; Wettwer E
Cardiovasc Res; 2011 Mar; 89(4):776-85. PubMed ID: 21159668
[TBL] [Abstract][Full Text] [Related]
10. Autonomic modulation of the frequency-dependent actions of diltiazem on the atrioventricular node in anesthetized dogs.
Nayebpour M; Talajic M; Jing W; Nattel S
J Pharmacol Exp Ther; 1990 Apr; 253(1):353-61. PubMed ID: 2329518
[TBL] [Abstract][Full Text] [Related]
11. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.
Tamargo J; Caballero R; Gómez R; Delpón E
Expert Opin Investig Drugs; 2009 Apr; 18(4):399-416. PubMed ID: 19335273
[TBL] [Abstract][Full Text] [Related]
12. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.
Shiroshita-Takeshita A; Sakabe M; Haugan K; Hennan JK; Nattel S
Circulation; 2007 Jan; 115(3):310-8. PubMed ID: 17224477
[TBL] [Abstract][Full Text] [Related]
13. In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions.
Nakashima H; Gerlach U; Schmidt D; Nattel S
Cardiovasc Res; 2004 Mar; 61(4):705-14. PubMed ID: 14985067
[TBL] [Abstract][Full Text] [Related]
14. Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans.
Walfridsson H; Anfinsen OG; Berggren A; Frison L; Jensen S; Linhardt G; Nordkam AC; Sundqvist M; Carlsson L
Europace; 2015 Mar; 17(3):473-82. PubMed ID: 25082948
[TBL] [Abstract][Full Text] [Related]
15. Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange.
Schotten U; de Haan S; Verheule S; Harks EG; Frechen D; Bodewig E; Greiser M; Ram R; Maessen J; Kelm M; Allessie M; Van Wagoner DR
Cardiovasc Res; 2007 Jan; 73(1):37-47. PubMed ID: 17157284
[TBL] [Abstract][Full Text] [Related]
16. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.
Ford J; Milnes J; Wettwer E; Christ T; Rogers M; Sutton K; Madge D; Virag L; Jost N; Horvath Z; Matschke K; Varro A; Ravens U
J Cardiovasc Pharmacol; 2013 May; 61(5):408-15. PubMed ID: 23364608
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological determinants of atrial fibrillation in sinus node dysfunction despite atrial pacing.
De Sisti A; Attuel P; Manot S; Fiorello P; Halimi F; Leclercq JF
Europace; 2000 Oct; 2(4):304-11. PubMed ID: 11194597
[TBL] [Abstract][Full Text] [Related]
18. Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.
Wolkenberg SE; Nolt MB; Bilodeau MT; Trotter BW; Manley PJ; Kett NR; Nanda KK; Wu Z; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Dinsmore CJ; Lindsley CW; Hartman GD
Bioorg Med Chem Lett; 2017 Feb; 27(4):1062-1069. PubMed ID: 28131713
[TBL] [Abstract][Full Text] [Related]
19. Effects of verapamil, zatebradine, and E-4031 on the pacemaker location and rate in response to sympathetic stimulation in dog hearts.
Furukawa Y; Miyashita Y; Nakajima K; Hirose M; Kurogouchi F; Chiba S
J Pharmacol Exp Ther; 1999 Jun; 289(3):1334-42. PubMed ID: 10336524
[TBL] [Abstract][Full Text] [Related]
20. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.
Olsson RI; Jacobson I; Iliefski T; Boström J; Davidsson Ö; Fjellström O; Björe A; Olsson C; Sundell J; Gran U; Gyll J; Malmberg J; Hidestål O; Emtenäs H; Svensson T; Yuan ZQ; Strandlund G; Åstrand A; Lindhardt E; Linhardt G; Forsström E; Högberg Å; Persson F; Andersson B; Rönnborg A; Löfberg B
Bioorg Med Chem Lett; 2014 Mar; 24(5):1269-73. PubMed ID: 24513046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
